Countable Labs raises $26M Series A led by ARCH for single-molecule PCR
What's the deal? Countable Labs, the company behind a single-molecule PCR technology it calls Countable PCR, has closed an oversubscribed $26M financing round. ARCH Venture Partners led the round, with F-Prime CapitalDealroom has a profile for this one. Try Dealroom → and Primer VenturesDealroom has a profile for this one. Try Dealroom → participating. The funds will go toward developing clinical products for cell and gene therapy, minimal residual disease (MRD) testing, biomarker validation, and vaccine quality control.
The company also hired Christopher Citraro, a nearly 20-year life sciences sales veteran from 10x Genomics, as vice president of global sales to drive commercial expansion.
Why now? Countable Labs says its initial clinical sample studies have validated the technology's robustness, and it is now ready to move from proof of concept to commercialisation. "2026 is a critical year for Countable Labs' momentum," said chief executive officer Giovanna Prout. "We must develop and globally market new products for key customer segments."
The company is targeting segments where digital PCR and next-generation sequencing currently dominate — markets that investors believe are ripe for disruption. "PCR technology is widespread, but ready for disruption from faster, less expensive, and more robust technologies," said Corey Ritter, partner at ARCH Venture Partners.
What could go wrong? Countable Labs is stepping into a crowded field. Digital PCR and next-generation sequencing are entrenched in clinical and industrial workflows, and displacing them requires not just better technology but regulatory clearances, lab adoption, and proven real-world performance at scale. Convincing labs to switch from established platforms is historically slow and expensive.
The company also faces well-funded competitors. Firms like Bio-Rad, Thermo Fisher Scientific, and Illumina have deep pockets, global distribution networks, and long-standing customer relationships.
The signal: ARCH Venture Partners, one of the most prolific life sciences investment funds, leading this oversubscribed round underscores deep-pocketed investor conviction that single-molecule diagnostics can unseat digital PCR incumbents. With cell and gene therapies advancing rapidly toward commercial scale, the bottleneck is increasingly shifting from discovery to precise, accessible quality control — exactly the gap an early-growth company like Countable Labs is positioning to fill.
Read more: Benzinga
